Skip to main content
Erschienen in: Annals of Surgical Oncology 5/2017

11.10.2016 | Endocrine Tumors

Cancer Registries: Can We Improve the Quality of Thyroid Cancer Data?

verfasst von: Colleen M. Kiernan, MD, MPH, Martin A. Whiteside, PhD, MSPH, Carmen C. Solorzano, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Cancer registries are used to report cancer care trends and outcomes. Information from these data sets is utilized to craft practice guidelines and management recommendations. Limited knowledge is available regarding the quality of the data contained within registries. We sought to determine the accuracy of a single variable, ‘surgery of the primary site’, in the Tennessee Cancer Registry (TCR).

Methods

A retrospective review of the TCR thyroid database was performed. Hospital facilities were classified as either Commission on Cancer (CoC) or non-CoC accredited. Certified Tumor Registrars at the TCR reviewed the abstracted text and/or telephoned the reporting facility staff to confirm the definitive thyroid procedure.

Results

A total of 921 thyroid cancer cases, diagnosed/treated at TN facilities during 2004–2011, were coded with thyroid lobectomy (TL). Overall, 369 (40 %) were incorrectly coded, of which 247(67 %) were changed to total thyroidectomy. The majority of cases (80 %) were reported by CoC facilities. When compared by facility type, 42 % of records submitted from CoC facilities contained incorrect codes for the variable ‘surgery of the primary site’ TL compared with 34 % of records submitted by non-CoC facilities (p = 0.047).

Conclusion

In this study of the TCR, 40 % of records contained inaccurate coding of the variable ‘surgery of the primary site’. Upon validation, 27 % of all records were changed from TL to total thyroidectomy. The rate of incorrect coding was higher in CoC reporting facilities than in non-CoC facilities. Using text-to-code re-abstraction audits and facility contact these discrepancies can be validated and corrected to improve data quality.
Literatur
2.
Zurück zum Zitat Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1–133.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Kiernan CM, Parikh AA, Parks LL, Solorzano CC. Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes? J Am Coll Surg. 2015;220(4):617–25.CrossRefPubMed Kiernan CM, Parikh AA, Parks LL, Solorzano CC. Use of radioiodine after thyroid lobectomy in patients with differentiated thyroid cancer: does it change outcomes? J Am Coll Surg. 2015;220(4):617–25.CrossRefPubMed
4.
Zurück zum Zitat Goffredo P, Thomas SM, Adam MA, Sosa JA, Roman SA. Impact of timeliness of resection and thyroidectomy margin status on survival for patients with anaplastic thyroid cancer: an analysis of 335 cases. Ann Surg Oncol. 2015;22(13):4166–74.CrossRefPubMed Goffredo P, Thomas SM, Adam MA, Sosa JA, Roman SA. Impact of timeliness of resection and thyroidectomy margin status on survival for patients with anaplastic thyroid cancer: an analysis of 335 cases. Ann Surg Oncol. 2015;22(13):4166–74.CrossRefPubMed
6.
Zurück zum Zitat Adam MA, Pura J, Goffredo P, Dinan MA, Hyslop T, Reed SD, et al. Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. J Clin Endocrinol Metab. 2015;100(1):115–21.CrossRefPubMed Adam MA, Pura J, Goffredo P, Dinan MA, Hyslop T, Reed SD, et al. Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. J Clin Endocrinol Metab. 2015;100(1):115–21.CrossRefPubMed
7.
Zurück zum Zitat Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260(4):601–5; discussion 5–7.CrossRefPubMedPubMedCentral Adam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, et al. Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients. Ann Surg. 2014;260(4):601–5; discussion 5–7.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Bilimoria KY, Bentrem DJ, Linn JG, Freel A, Yeh JJ, Stewart AK, et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery. 2007;142(6):906–13; discussion 913.e1-2.CrossRefPubMed Bilimoria KY, Bentrem DJ, Linn JG, Freel A, Yeh JJ, Stewart AK, et al. Utilization of total thyroidectomy for papillary thyroid cancer in the United States. Surgery. 2007;142(6):906–13; discussion 913.e1-2.CrossRefPubMed
9.
10.
Zurück zum Zitat Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer. 1998;83(12):2638–48. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer. 1998;83(12):2638–48.
11.
Zurück zum Zitat Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010;136(11):1055–61.CrossRefPubMed Mendelsohn AH, Elashoff DA, Abemayor E, St John MA. Surgery for papillary thyroid carcinoma: is lobectomy enough? Arch Otolaryngol Head Neck Surg. 2010;136(11):1055–61.CrossRefPubMed
12.
Zurück zum Zitat Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134–42.CrossRefPubMed Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer. 2006;107(9):2134–42.CrossRefPubMed
14.
Zurück zum Zitat Shaha AR. The National Cancer Data Base Report on thyroid carcinoma: reflections of practice patterns. Cancer. 1998;83(12):2434–6. Shaha AR. The National Cancer Data Base Report on thyroid carcinoma: reflections of practice patterns. Cancer. 1998;83(12):2434–6.
15.
Zurück zum Zitat Shaha AR. Extent of surgery for papillary thyroid carcinoma: the debate continues. Comment on “surgery for papillary thyroid carcinoma”. Arch Otolaryngol Head Neck Surg. 2010;136(11):1061–3.CrossRefPubMed Shaha AR. Extent of surgery for papillary thyroid carcinoma: the debate continues. Comment on “surgery for papillary thyroid carcinoma”. Arch Otolaryngol Head Neck Surg. 2010;136(11):1061–3.CrossRefPubMed
16.
Zurück zum Zitat Commission on Cancer. Facility Oncology Registry Data Standards. Chicago: American College of Surgeons; 2016. Commission on Cancer. Facility Oncology Registry Data Standards. Chicago: American College of Surgeons; 2016.
17.
Zurück zum Zitat Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40(8 Suppl):IV-43–IV-8. Cooper GS, Virnig B, Klabunde CN, Schussler N, Freeman J, Warren JL. Use of SEER-Medicare data for measuring cancer surgery. Med Care. 2002;40(8 Suppl):IV-43–IV-8.
Metadaten
Titel
Cancer Registries: Can We Improve the Quality of Thyroid Cancer Data?
verfasst von
Colleen M. Kiernan, MD, MPH
Martin A. Whiteside, PhD, MSPH
Carmen C. Solorzano, MD
Publikationsdatum
11.10.2016
Verlag
Springer International Publishing
Erschienen in
Annals of Surgical Oncology / Ausgabe 5/2017
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5612-6

Weitere Artikel der Ausgabe 5/2017

Annals of Surgical Oncology 5/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.